

Product datasheet

anti-CA19-9 (SLea) mouse monoclonal, 121SLE, purified

Short overview

Cat. No. 691523

Quantity1 ml (100 μ g/ml)Concentration100 μ g/ml

Product description

HostMouseAntibody TypeMonoclonalIsotypeIgM kappaClone121SLE

Immunogen Ten precipitin lines obtained after immunodiffusion using mAb NS19-9 and mucins isolated from

an ovarian cyst of a 0Lea+b- patient

Formulation PBS with 0.02% sodium azide

Conjugate Unconjugated

Purification Affinity chromatography

Storage 2-8°C

Intended use Research use only
Application ELISA, FACS, IHC

Reactivity Human

Applications

ELISA Assay dependent

Flow Cytometry (FACS) 0.5-1.0 μg/million cells in 0.1 ml


 $\begin{array}{ll} \mbox{Immunohistochemistry (IHC) - frozen} & 1:50-1:100 \ (1-2 \ \mu g/ml) \\ \mbox{Immunohistochemistry (IHC) - paraffin} & 1:50-1:100 \ (1-2 \ \mu g/ml) \\ \end{array}$

Background

121SLE reacts with CA19-9 (>400 kDa) or sialyl Lea structure, which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lea and/or Leb blood group antigens. 121SLE also binds to some extend to the afuco version of SLea (LSTa; CA50). In normal tissues, CA19-9 is present in ductal epithelium of the breast, kidney, salivary, gland and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine and pancreas. 121SLE was typed in the ISOBM TD-6 workshop.

Positive control: stomach or colon carcinoma.

Product images



Gastric carcinoma